Canada Post Corp Registered Pension Plan Has $1.99 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Canada Post Corp Registered Pension Plan lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 87.3% in the fourth quarter, HoldingsChannel reports. The firm owned 2,575 shares of the biopharmaceutical company’s stock after purchasing an additional 1,200 shares during the period. Canada Post Corp Registered Pension Plan’s holdings in Regeneron Pharmaceuticals were worth $1,988,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of REGN. Dodge & Cox boosted its position in shares of Regeneron Pharmaceuticals by 18.9% in the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after purchasing an additional 724,562 shares during the period. AQR Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 528.7% in the 3rd quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock valued at $405,596,000 after purchasing an additional 606,612 shares during the period. Invesco Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 38.0% in the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after purchasing an additional 408,649 shares during the period. Caisse de depot et placement du Quebec boosted its position in shares of Regeneron Pharmaceuticals by 115.4% in the 3rd quarter. Caisse de depot et placement du Quebec now owns 462,502 shares of the biopharmaceutical company’s stock valued at $260,051,000 after purchasing an additional 247,780 shares during the period. Finally, Man Group plc boosted its position in shares of Regeneron Pharmaceuticals by 257.6% in the 3rd quarter. Man Group plc now owns 271,707 shares of the biopharmaceutical company’s stock valued at $152,773,000 after purchasing an additional 195,724 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This trade represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $698.25 on Monday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The firm has a market capitalization of $73.82 billion, a PE ratio of 17.01, a PEG ratio of 1.55 and a beta of 0.30. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $744.69 and a two-hundred day moving average price of $746.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same period last year, the company posted $8.22 EPS. The business’s quarterly revenue was up 19.0% compared to the same quarter last year. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.1 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Barclays decreased their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Evercore raised their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Wells Fargo & Company decreased their price objective on Regeneron Pharmaceuticals from $825.00 to $800.00 and set an “equal weight” rating for the company in a research report on Thursday, April 30th. Truist Financial decreased their price objective on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating for the company in a research report on Thursday, April 30th. Finally, Zacks Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $826.59.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.